Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
$2.15
+1.9%
$1.95
$1.29
$3.51
$194.51M0.2213,151 shs10,387 shs
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$7.65
$7.06
$3.85
$8.98
$614.79M1.25665,612 shs513,206 shs
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$10.96
-1.4%
$10.70
$6.73
$12.61
$761.20M0.024,439 shs23,035 shs
Urogen Pharma stock logo
URGN
Urogen Pharma
$19.40
+1.8%
$12.52
$3.42
$19.74
$880.60M1.121.24 million shs1.01 million shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
+1.90%+5.39%+18.13%-4.87%+0.23%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
0.00%-8.60%+10.55%+5.52%+46.27%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-1.35%+6.82%+2.91%+21.52%+28.19%
Urogen Pharma stock logo
URGN
Urogen Pharma
+1.78%+2.37%+49.69%+68.55%+17.93%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
2.352 of 5 stars
3.75.00.00.00.01.70.0
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
4.145 of 5 stars
3.53.00.04.81.12.50.6
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
3.0013 of 5 stars
3.55.00.00.03.20.00.6
Urogen Pharma stock logo
URGN
Urogen Pharma
4.6169 of 5 stars
4.54.00.04.52.42.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
3.33
Buy$11.00411.63% Upside
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
3.00
Buy$24.00213.73% Upside
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
3.00
Buy$30.00173.72% Upside
Urogen Pharma stock logo
URGN
Urogen Pharma
3.00
Buy$32.8669.37% Upside

Current Analyst Ratings Breakdown

Latest IPHA, URGN, PHAR, and MGTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/28/2025
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
7/8/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
7/7/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
6/16/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$50.00
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetNeutral ➝ Neutral$16.00
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Buy$31.00
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$23.00 ➝ $47.00
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $30.00
6/12/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
6/3/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$36.00 ➝ $10.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
$21.77M9.10N/AN/A$0.11 per share19.55
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$33.28M18.47N/AN/A$0.87 per share8.79
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$297.20M2.53$0.07 per share149.88$3.25 per share3.37
Urogen Pharma stock logo
URGN
Urogen Pharma
$90.40M9.91N/AN/A($0.21) per share-92.38
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
-$53.53MN/A0.00N/AN/AN/AN/A9/17/2025 (Estimated)
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$147.79M-$2.32N/A20.13N/A-484.90%-241.05%-62.93%8/11/2025 (Estimated)
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-$11.84M-$0.13N/A365.33N/A-2.19%-3.38%-1.82%N/A
Urogen Pharma stock logo
URGN
Urogen Pharma
-$126.87M-$3.18N/AN/AN/A-150.68%-97,487.15%-49.57%8/7/2025 (Estimated)

Latest IPHA, URGN, PHAR, and MGTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.52N/AN/AN/A$8.00 millionN/A
8/7/2025Q2 2025
Urogen Pharma stock logo
URGN
Urogen Pharma
-$0.85N/AN/AN/A$23.06 millionN/A
7/31/2025Q2 2025
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-$0.10$0.06+$0.16$0.06$70.36 million$93.20 million
5/13/2025Q1 2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.38-$0.51-$0.13-$0.51$4.44 million$1.93 million
5/12/2025Q1 2025
Urogen Pharma stock logo
URGN
Urogen Pharma
-$0.83-$0.92-$0.09-$0.92$22.71 million$20.25 million
5/8/2025Q1 2025
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-$0.25-$0.22+$0.03-$0.22$67.74 million$79.09 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
N/AN/AN/AN/AN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
N/AN/AN/AN/AN/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
N/AN/AN/AN/AN/A
Urogen Pharma stock logo
URGN
Urogen Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
2.52
2.60
2.60
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
2.34
1.53
1.51
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.39
2.76
2.00
Urogen Pharma stock logo
URGN
Urogen Pharma
N/A
5.65
5.47

Institutional Ownership

CompanyInstitutional Ownership
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
0.16%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
67.48%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.03%
Urogen Pharma stock logo
URGN
Urogen Pharma
91.29%

Insider Ownership

CompanyInsider Ownership
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
31.89%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
7.50%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
2.07%
Urogen Pharma stock logo
URGN
Urogen Pharma
5.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
22092.18 million62.79 millionNot Optionable
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
30080.36 million74.34 millionOptionable
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
28068.51 million67.10 millionNot Optionable
Urogen Pharma stock logo
URGN
Urogen Pharma
20046.20 million43.85 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Innate Pharma stock logo

Innate Pharma NASDAQ:IPHA

$2.17 +0.06 (+2.84%)
As of 08/1/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

MeiraGTx stock logo

MeiraGTx NASDAQ:MGTX

$7.65 0.00 (0.00%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$7.65 0.00 (0.00%)
As of 08/1/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Pharming Group stock logo

Pharming Group NASDAQ:PHAR

$10.96 -0.15 (-1.35%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$10.99 +0.03 (+0.26%)
As of 08/1/2025 05:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Urogen Pharma stock logo

Urogen Pharma NASDAQ:URGN

$19.40 +0.34 (+1.78%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$19.44 +0.04 (+0.21%)
As of 08/1/2025 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.